Kae Capital

Kae Capital is a highly active Mumbai-based early-stage venture firm with a sector-agnostic pattern across Indian technology, including digital health. Check sizes of $1M to $5M place the firm in the institutional seed range, with the ability to lead priced rounds or co-lead alongside marquee Indian seed names. Kae’s footprint in Indian early-stage venture is established, with multiple fund vintages and deep founder networks.

The firm’s natural fit is with Indian founders building software-led companies with clear digital adoption tailwinds, including digital health platforms targeting consumers, payers, providers, or pharma. The firm is not specifically AI-focused; AI-first founders should expect commercial diligence rather than model-architectural diligence. The right founder profile is a credentialed team with prior operational experience or technical pedigree, building in a category with venture-scale TAM and clear unit economics. Founders building deep biotech or clinical assets requiring patient capital and FDA-savvy boards will find better fits in dedicated healthcare specialty funds.

Geographically, Kae’s advantage is its density of Indian founder relationships and its ability to introduce founders to follow-on Series A and B investors. For Indian-anchored founders, this network value is meaningful. For founders without Indian operational ties, the strategic logic is thinner.

The right entry path is a warm intro from a portfolio founder, a fellow Indian VC, or a senior operator at one of the Indian unicorns. Kae reads partner-led decks; cold inbound is workable when there is clear thesis fit and traction signal. The pitch should lead with the founder team, the Indian customer wedge, early evidence of demand, and a credible follow-on plan. Healthcare-specific pitches should explain how the product navigates Indian payer and provider dynamics and what the path to durable margin looks like.

Caveats. Sector-agnostic firms have shallower healthcare-specific operational expertise than dedicated healthcare investors; expect generalist diligence. The healthcare-specific portfolio is real but not the firm’s central thesis; reference calls with existing health-sector founders are essential. The $1M to $5M range is broad; clarify expected ownership and lead status early. For an Indian early-stage health-tech founder with strong team and traction signals, Kae is among the credible institutional seed partners; for narrow clinical or therapeutic plays, dedicated specialty funds are a better fit.